The Fiji Medical Association (FMA) has urged the Government to adopt a careful, evidence-based approach to planned drug testing of public officials, warning that poorly designed programmes risk misinterpretation of results, legal disputes and unfair consequences for workers. In a media release, FMA President Dr Ronal Kumar described drug testing as a medical, ethical and public‑health issue that must be grounded in science and human‑rights principles rather than treated solely as a disciplinary measure.
Dr Kumar acknowledged the Government’s move to introduce drug testing among officials and said the association shares concern about illicit drug use—particularly methamphetamine—as a serious national problem that threatens public safety and confidence in institutions. But he stressed that testing without a clear policy framework could do more harm than good. “The FMA supports efforts to protect public safety, integrity and confidence in public institutions,” he said, “however, drug testing is a medical, ethical and public‑health issue and not merely a disciplinary one.”
The association highlighted technical limitations of common screening methods, noting that routine urine tests detect drug metabolites rather than current impairment. A positive result therefore does not necessarily indicate intoxication or an immediate inability to work safely, Dr Kumar warned, and can be misread if programs lack confirmatory laboratory processes and independent medical oversight. International experience, he added, shows that blanket testing regimes tend to produce stigma, legal challenges and unfair outcomes when safeguards are absent.
Instead of whole‑of‑service or blanket testing, the FMA advocates a risk‑based, targeted approach. Testing should be focused on safety‑sensitive roles, be triggered by incidents or reasonable suspicion, and form part of a broader occupational health strategy that includes counselling and treatment. “Drug testing is not a single solution,” Dr Kumar said, pointing out there is little international precedent for mass testing of civil service workforces without a comprehensive policy framework.
The FMA set out a series of safeguards it wants built into any national drug‑testing regime: an explicit national policy; risk‑based and targeted testing criteria; reflex confirmatory laboratory testing; independent medical review of results; protection of individual rights and privacy; and guaranteed access to counselling, treatment and rehabilitation services for those identified with substance use disorders. The association also urged recognition that substance use disorders are medical conditions that should be managed through treatment and rehabilitation rather than punitive measures alone.
The statement positions the FMA as ready to work with government and other stakeholders to develop what Dr Kumar described as a “credible, humane and effective” framework based on international best practice and medical ethics. The call comes amid broader government efforts to strengthen the national response to drugs, which have included recruitment for a Counter Narcotics Bureau and community mobilization campaigns engaging faith groups and traditional leaders. How policymakers respond to the FMA’s concerns will shape whether future testing is implemented as part of a balanced public‑health strategy or as a primarily punitive measure with potential for unintended social and legal fallout.